Search the Newsreel

AbbVie Number of Employees 2026 | Employee Count & Headcount Data

As of March 2026, AbbVie (ABBV) has approximately 57,960 total employees worldwide, a growth of 11.0% since 2023. The company is actively hiring, with 2,862 job postings in 2026, and its workforce is concentrated in the United States, followed by India and Ireland. The …

LatentView Analytics reports 6 pc decline in Q1 profit

SUPV Stock Price and Chart — NYSE:SUPV

This article provides an overview of Grupo Supervielle S.A. (NYSE: SUPV) stock performance, key financial statistics, and company details. It includes price changes over various periods, market capitalization, dividend yield, EPS, revenue, and information about the company's operational segments and headquarters. The article also …

Avient (AVNT) Nears Its Earnings Test, Is The 14% Undervalued View Priced In?

View United Real Estate Development Company Revenue Breakdown – TADAWUL:9591

AbbVie Trims Full-Year Profit Outlook Due to Apogee Acquisition

AbbVie has revised its full-year profit forecast downwards as a direct consequence of its recent acquisition of Apogee Therapeutics. This adjustment reflects the financial impact and integration costs associated with the acquisition, signaling a change in the company's expected earnings for the fiscal year.

RVSB Q2 2026 Earnings: EPS Beat Signals Solid Operational Execution - Guidance Accuracy Score

Riverview Bancorp (NASDAQ:RVSB) Rating Lowered to Sell at Wall Street Zen

Wall Street Zen downgraded Riverview Bancorp (NASDAQ:RVSB) from "hold" to "sell," leading to an average "Reduce" rating for the company from MarketBeat. Despite beating earnings and revenue expectations in its recent quarterly report, Riverview Bancorp posted a negative net margin. The stock opened at …

RVSB|Riverview Bancorp Inc|Price:5.300|Chg%:+0.010

Riverview Bancorp Inc (RVSB) shows healthy fundamentals and good growth potential, with a "Buy" rating from analysts and a highest price target of $7.00. The stock is considered fairly valued and institutional ownership is very high, despite a recent decrease in holdings. The company …

AbbVie (ABBV) Stock Could Sit Below Fair Value While Earnings Look Rich

Riverview Bancorp Inc Revenue Breakdown – NASDAQ:RVSB

Riverview Bancorp Inc. (NASDAQ: RVSB) reported its revenue breakdown, with Banking Operations, Trust and Investment Services being its top-performing segment, generating $43.08 million last year, down from $50.60 million the previous year. All of the company's revenue came from the United States, totaling $43.08 …

AbbVie's Skyrizi and Rinvoq Launches Support Lengthy Patent Protection and a Wide Moat

AbbVie's key drugs Skyrizi and Rinvoq are providing strong support for the company's lengthy patent protection and wide economic moat. Despite biosimilar competition impacting Humira revenue in 2023, AbbVie returned to growth in 2024, demonstrating the resilience of its diversified portfolio. The company maintains …

Why AbbVie Stock Slumped Today

High-flying pharmaceutical company AbbVie (NYSE: ABBV) has seen its stock rise in many recent sessions. Yet Friday's wasn't one of them, as the company's shares took a nearly 3% loss on the back of a second-quarter earnings report that investors found uninspiring. Another double-digit …

AbbVie (ABBV) Wins EU Approval For RINVOQ In Vitiligo And Alopecia

AbbVie (ABBV) has received European Commission approval for its drug RINVOQ (upadacitinib) for new indications in the EU. RINVOQ is now approved as the first systemic treatment for non-segmental vitiligo and as a systemic option for severe alopecia areata in adults and adolescents. These …

AbbVie Inc (ABBV) (Q2 2026) Earnings Call Highlights: Robust Growth Driven by Skyrizi and ...

This article first appeared on GuruFocus. Release Date: July 31, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points AbbVie Inc (NYSE:ABBV) delivered another excellent quarter with total net revenues of nearly $17 billion, …

AVNT|Avient Corp|Price:36.320|Chg%:-0.350

This article provides a comprehensive stock analysis of Avient Corp (AVNT) by TradingKey, highlighting its healthy fundamentals, high growth potential, and fair valuation within the Chemicals industry. Despite recent weak stock market performance, the company shows strong fundamentals and is considered suitable for range-bound …

Grupo Supervielle SA (SUPV) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Grupo Supervielle SA (SUPV), detailing its current price momentum score, support and resistance levels, and key technical indicators. The stock is currently trading between resistance at 10.25 and support at 8.85, making it suitable for range-bound swing …

(NAVI) Volatility Zones as Tactical Triggers

This article provides an analysis of Navient Corporation (NASDAQ: NAVI) using AI-generated signals and institutional trading strategies. Key findings include strong near and mid-term sentiment but a weak long-term outlook, with a significant risk-reward short setup. The analysis offers specific entry, target, and stop-loss …

AbbVie Earnings Beat Forecasts as Skyrizi Sales Soar 24%. Why the Stock Is Falling.

AbbVie slashes its full-year guidance to account for its pending acquisition of Apogee Therapeutics. Continue Reading

ABBV Beats on Q2 Earnings & Sales, Cuts '26 EPS View, Stock Down

AbbVie ABBV reported second-quarter 2026 adjusted EPS of $3.65, which beat the Zacks Consensus Estimate of $3.64. The reported figure also exceeded the company's guidance of $3.57-$3.61 per share, issued earlier in July 2026. Earnings rose 22.9% year over year. ABBV's revenues of $16.99 …

Enterprise value to EBIT forward of Viemed Healthcare, Inc. – NASDAQ:VMD

The article focuses on the "Enterprise value to EBIT forward" metric for Viemed Healthcare, Inc. (NASDAQ: VMD). It is a financial data point presented on TradingView, indicating the company's valuation relative to its future earnings before interest and taxes.

AbbVie Beats but Cuts Guidance on $10.9 Billion Acquisition

This article first appeared on GuruFocus. AbbVie (NYSE:ABBV) fell 3.46% premarket after trimming full-year guidance alongside second-quarter results that beat on both lines. Net revenues rose 10.2% to $16.99 billion against the $16.78 billion analysts expected, and adjusted diluted earnings of $3.65 a share …

AbbVie Stock Falls as Guidance Cut Overshadows Strong Q2 Earnings Beat

AbbVie (NYSE: ABBV) shares fell after the company trimmed its full-year earnings guidance, despite reporting strong second-quarter earnings and revenue beats. The guidance reduction is primarily attributed to the anticipated acquisition of Apogee Therapeutics, which is expected to negatively impact 2026 earnings, although underlying …

AbbVie (ABBV) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

For the quarter ended June 2026, AbbVie (ABBV) reported revenue of $16.99 billion, up 10.2% over the same period last year. EPS came in at $3.65, compared to $2.97 in the year-ago quarter. The reported revenue represents a surprise of +1.07% over the Zacks …

AbbVie Q2 2026 earnings: profit forecast cut for Apogee deal

AbbVie beat second-quarter profit estimates due to strong immunology sales but announced a cut in its full-year adjusted earnings forecast by 14 cents per share. This reduction is attributed to the planned acquisition of Apogee Therapeutics for approximately $10.9 billion. The stock subsequently dropped …

AbbVie’s (NYSE:ABBV) Q2 CY2026: Beats On Revenue

AbbVie's (NYSE:ABBV) Q2 CY2026: Beats On Revenue Pharmaceutical company AbbVie (NYSE:ABBV) beat Wall Street's revenue expectations in Q2 CY2026, with sales up 10.2% year on year to $16.99 billion. Its non-GAAP profit of $3.65 per share was 1.2% above analysts' consensus estimates. Is now …

AbbVie (ABBV) Q2 Earnings and Revenues Beat Estimates

AbbVie (ABBV) came out with quarterly earnings of $3.65 per share, beating the Zacks Consensus Estimate of $3.64 per share. This compares to earnings of $2.97 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings …

AbbVie Bought Apogee to Strengthen Its Portfolio. Now It’s Cutting Earnings Guidance.

AbbVie shares took a hit Friday after costs related to the drugmaker’s acquisition of Apogee Therapeutics forced a cut to its full-year profit outlook. Second-quarter revenue jumped 10% to nearly $17 billion, beating the $16.8 billion consensus estimate among analysts polled by FactSet. AbbVie …

AbbVie shares fall on earnings miss and weak guidance

Investing.com -- AbbVie Inc. (NYSE: ABBV) reported second-quarter earnings before the open on Friday, missing profit expectations, although revenue beat the consensus estimate. Adjusted earnings per share came in at $3.65, missing analyst estimates of $3.71, while revenue of $16.99 billion exceeded the consensus …

Las acciones de AbbVie caen tras decepcionar en resultados y guidance

AbbVie trims 2026 profit forecast on Apogee buy, beats second-quarter estimates

July 31 (Reuters) - AbbVie trimmed its 2026 profit forecast on Friday to account for its planned Apogee Therapeutics ‌acquisition, while topping second-quarter estimates on strong immunology drug ‌sales. Shares of the drugmaker fell more than 4% in premarket trading. In June, ​AbbVie agreed …

AbbVie trims 2026 profit view on Apogee deal, tops second-quarter estimates

AbbVie slightly reduced its 2026 profit forecast due to its planned acquisition of Apogee Therapeutics, which is expected to cut full-year earnings by 4 cents per share. Despite this, the company exceeded second-quarter estimates with strong immunology drug sales from Skyrizi and Rinvoq, counteracting …

AbbVie Earnings Preview: Immunology portfolio remains in focus amid Humira decline

[AbbVie] hapabapa AbbVie (ABBV [https://seekingalpha.com/symbol/ABBV]) is projected to report a solid second-quarter print, with double-digit growth seen for both top and bottom lines. EPS is expected to go up 67% Y/Y to $3.61 [https://seekingalpha.com/symbol/ABBV/earnings/estimates]. This is the higher end of management’s forecast for the …

AbbVie Sales Beat Estimates as Botox Shows Signs of Revival

AbbVie Inc. exceeded Wall Street's second-quarter profit and sales expectations, driven by robust performance in its immunology and neuroscience divisions. The company's top-selling drugs, including the wrinkle-smoothing injection Botox, outperformed forecasts, with Botox sales showing improvement for the third consecutive quarter. Adjusted earnings also …

Riverview Bancorp, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Riverview Bancorp (NASDAQ:RVSB) recently surpassed analyst expectations for its first-quarter earnings, reporting EPS of US$0.08, beating predictions by 14%. While revenues of US$15 million were in line, the sole analyst covering the company has slightly downgraded future EPS forecasts but increased the price target …

VMD Q2'26 Earnings: EPS estimate is 0.12 USD

Viemed Healthcare, Inc. (VMD) is expected to announce its Q2'26 earnings on August 3rd, with an estimated EPS of $0.12 and revenue of $78.00 million. This article provides a comparative table of reported and estimated revenue and EPS figures for recent quarters, highlighting surprises.